Selexys Pharmaceuticals Mar 2008 - Nov 2016
Chief Executive Officer and President
Tetherex Pharmaceuticals Mar 2008 - Nov 2016
Chief Executive Officer and Chairman of the Bod
Alexion Pharmaceuticals Apr 1992 - Feb 2008
Cofounder and Senior Vice President
Education:
Yale University 1990 - 1992
University of Oklahoma College of Medicine 1986 - 1990
Doctorates, Doctor of Philosophy, Microbiology, Immunology
Skills:
Biotechnology Immunology Lifesciences Clinical Development Technology Transfer Pharmaceutical Industry Drug Development Biopharmaceuticals Commercialization Oncology Drug Discovery Medical Writing Clinical Trials Molecular Biology Hematology Clinical Research Fda Dermatology
Plateau Valley Medical Clinic 58128 Hwy 330, Collbran, CO 81624 9704873565 (phone), 9704873568 (fax)
Education:
Medical School University of Kansas School of Medicine Graduated: 1991
Procedures:
Allergen Immunotherapy Arthrocentesis Continuous EKG Destruction of Benign/Premalignant Skin Lesions Electrocardiogram (EKG or ECG) Pulmonary Function Tests Skin Tags Removal Vaccine Administration
Conditions:
Allergic Rhinitis Benign Prostatic Hypertrophy Breast Disorders Candidiasis Cardiac Arrhythmia
Languages:
English Spanish
Description:
Dr. Rollins graduated from the University of Kansas School of Medicine in 1991. He works in Collbran, CO and specializes in Family Medicine. Dr. Rollins is affiliated with Community Hospital and St Marys Hospital & Medical Center.
Mark J. Evans - Cheshire CT Louis A. Matis - Southport CT Eileen Elliott Mueller - East Haven CT Steven H. Nye - Mequon WI Scott Rollins - Monroe CT Russell P. Rother - Cheshire CT Jeremy P. Springhorn - Cheshire CT Stephen P. Squinto - Bethany CT Thomas C. Thomas - Madison CT James A. Wilkins - Woodbridge CT
The use of anti-C5 antibodies, e. g. , monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
Peter J. Sims - Mequon WI, US Alfred L. M. Bothwell - Guilford CT, US Eileen A. Elliot - New Haven CT, US Richard A. Flavell - Killingworth CT, US Joseph Madri - North Branford CT, US Scott Rollins - Monroe CT, US Leonard Bell - Woodbridge CT, US Stephen Squinto - Irvington NY, US
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK Yale University - New Haven CT
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i. e. , hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.
Methods Of Inhibiting The Psgl-1-Mediated Adhesion And Chemokine-Mediated Migration With Psgl-1-Specific Antibodies
The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for such antibodies and binding fragments thereof and to methods of therapeutic use thereof.
Methods For The Preparation Of Retroviral Particles And Cell Lines Deficient In The Alpha-Galactosyl Epitope
RUSSELL P. ROTHER - CHESHIRE CT, US SCOTT A. ROLLINS - OXFORD CT, US WILLIAM L. FODOR - MADISON CT, US JEREMY P. SPRINGHORN - GUILFORD CT, US STEPHEN P. SQUINTO - BETHANY CT, US
Methods and compositions are provided for facilitating gene therapy procedures involving the transduction of target cells with retroviral vector particles in the presence of complement containing body fluids. The reduction of levels of galactose alpha (1,3) galactosyl epitopes on the retroviral vector particles and/or the blockade of antibody binding to such epitopes have been found to render the particles less sensitive to inactivation by complement mediated mechanisms, and to thus allow transduction in the presence of complement containing body fluids. Means are provided for obtaining such reductions.
RICHARD ALVAREZ - EDMOND OK, US SCOTT ROLLINS - OKLAHOMA CITY OK, US
International Classification:
G01N 33/53
US Classification:
435 724, 436501, 435 722
Abstract:
The present invention is directed to antibodies and binding fragments thereof, which bind with high affinity and specificity to human P-selectin glycoprotein ligand 1 (PSGL-1) and which block both selectin and chemokine binding to PSGL-1 expressed on leukocytes, lymphocytes and endothelial cells and thus which inhibit migration and/or rolling of these cells and to methods for screening for inhibitory compounds including such antibodies and binding fragments thereof and to methods of therapeutic use thereof.
Anti-P-Selectin Antibodies And Methods Of Their Use And Identification
Scott Rollins - Oklahoma City OK, US Richard Alvarez - Edmond OK, US Russell Rother - Oklahoma City OK, US Rodger P. McEver - OKlahoma City OK, US Ziad S. Kawar - Oklahoma City OK, US
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Anti-P-Selectin Antibodies And Methods Of Their Use And Identification
Scott Rollins - Oklahoma City OK, US Richard Alvarez - Edmond OK, US Russell Rother - Oklahoma City OK, US Rodger P. McEver - Oklahoma City OK, US Ziad S. Kawar - Oklahoma City OK, US
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Anti-P-Selectin Antibodies And Methods Of Their Use And Identification
Scott Rollins - Oklahoma City OK, US Richard Alvarez - Edmond OK, US Russell Rother - Oklahoma City OK, US Rodger P. McEver - Oklahoma City OK, US Ziad S. Kawar - Oklahoma City OK, US
Antibodies are disclosed which bind specifically to P-selectin and which block the binding of PSGL-1 to P-selectin. These anti-P-selectin antibodies may also cause dissociation of preformed P-selectin/PSGL-1 complexes. The disclosure identifies a heretofore unrecognized, near N-terminal, antibody binding domain (a conformational epitope) of P-selectin to which the function-blocking antibodies (which may be chimeric, human or humanized antibodies for example) bind. Antibodies are disclosed which bind to the conformational epitope of P-selectin and which have a dual function in blocking binding of PSGL-1 to P-selectin, and in causing dissociation of preformed P-selectin/PSGL-1 complexes. Such single and dual function anti-P-selectin antibodies and binding fragments thereof may be used in the treatment of a variety of inflammatory and thrombotic disorders and conditions. Screening methods for identifying such antibodies are also disclosed.
Name / Title
Company / Classification
Phones & Addresses
Scott Rollins
NAI Wheeler Kenwheel Inc. Fidelis Commercial Real Estate Services. NAI Fidelis Real Estate - Commercial. Real Estate. Property Management - Industrial & Commercial
Scott Rollins, M.D., is board certified with the American Board of Family Practice and the American Board of Anti-Aging and Regenerative Medicine. He specializes in bioidentical hormone replacement, thyroid and adrenal disorders, fibromyalgia and other complex medical conditions. He is founder and m